Leptomeningeal disease (LMD) is prevalent in patients with gliomas that contain histone-3 (H3) mutations, new research suggests.
“The 2016 WHO classification described a subtype of midline gliomas harboring H3 K27M mutations, and the 2021 edition added a new subtype of hemispheric diffuse gliomas with H3 G34R/V mutations,” according to Dr Maria Diaz and colleagues at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, USA.